Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 0.65 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.65 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.65 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.43 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.43 |
| ▸ | DRD1 known ✓ | P21728 | 4/20 | 0.42 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.42 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | F3 | P13726 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7336826 | 0.98 | DRD2 (0.67) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL2955073 | 0.87 | DRD2 (0.51) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL11523807 | 0.85 | DRD2 (0.52) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL8339560 | 0.84 | DRD2 (0.51) | DRD2DRD3DRD4LMNATSHR | |
| Hydrochloric Acid SCHEMBL7331896 | 0.82 | DRD2 (0.69) | DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL7331890 | 0.82 | DRD2 (0.69) | DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL7271841 | 0.82 | DRD2 (0.59) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL2949669 | 0.81 | DRD2 (0.49) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL8767680 | 0.81 | DRD2 (0.70) | DRD2DRD3DRD4 | |
| SCHEMBL8767685 | 0.81 | DRD2 (0.70) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102652-A1 | Optically active2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them | CHIESI FARMACEUTICI S.P.A. (IT) | 2004-05-27 | — | — | US | disclosed |
| CN-1137085-C | Process for preparation of 5,6-dihydroxyl-2-amino-1,2,3,4-tetrahydronaphthalene derivatives | ������˹ҩƷ��˾ | 2004-02-04 | — | — | CN | disclosed |
| EP-1280759-A1 | OPTICALLY ACTIVE 2-AMINOTETRALIN DERIVATIVES, THE PROCESSES FOR THE PREPARATION THEREOF AND THE THERAPEUTICAL USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHIESI FARMACEUTICI S.p.A. (IT) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001085668-A1 | OPTICALLY ACTIVE 2-AMINOTETRALIN DERIVATIVES, THE PROCESSES FOR THE PREPARATION THEREOF AND THE THERAPEUTICAL USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHIESI FARMACEUTICI S.P.A. (IT) | 2001-11-15 | — | — | WO | disclosed |
| CN-1278528-A | Process for preparation of 5,6-dihydroxyl-2-amino-1,2,3,4-tetrahydronaphthalene derivatives | CHIESI PHARMACEUTICAL S P A (IT) | 2001-01-03 | — | — | CN | disclosed |
| CN-1278526-A | Process for preparation of 5,6-dihydroxyl-2-amino-1,2,3,4-tetrahydronaphthalene derivatives | CHIESI PHARMACEUTICAL S P A (IT) | 2001-01-03 | — | — | CN | disclosed |
| CN-1278527-A | Process for preparation of 5,6-dihydrxyl-2-amino-1,2,3,4-tetrahydronaphthalene derivatives | CHIESI PHARMACEUTICAL S P A (IT) | 2001-01-03 | — | — | CN | disclosed |
| EP-0788472-B1 | A PROCESS FOR THE PREPARATION OF 5,6-DIHYDROXY-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | CHIESI FARMA SPA (IT) | 2000-08-02 | — | — | EP | disclosed |
| US-6034277-A | Process for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2000-03-07 | — | — | US | disclosed |
| US-5936125-A | Process for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 1999-08-10 | — | — | US | disclosed |
| US-5710336-A | Process for the preparation of 5-6-dihydroxy-2-amino-1, 2, 3, 4-tetrahydronaphthalene derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 1998-01-20 | — | — | US | disclosed |
| US-4584293-A | LOWER HEART RATE AND OXYGEN REQUIREMENT | DR. KARL THOMAE GMBH (DE) | 1986-04-22 | — | — | US | disclosed |
| EP-0161604-A2 | Aminotetralin derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102652-A1 | Optically active2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them | AADAT, AASDHPPT, AAAS | DRD2 594/4885DRD3 1242/4885DRD4 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.